BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11683823)

  • 1. Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-beta 1 type I receptor expression.
    Baan CC; van Riemsdijk-van Overbeeke IC; Balk AH; Vantrimpont PM; Mol WM; Knoop CJ; Niesters HG; Maat LP; Weimar W
    Clin Transplant; 2001 Aug; 15(4):276-83. PubMed ID: 11683823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production.
    Jiang H; Wynn C; Pan F; Ebbs A; Erickson LM; Kobayashi M
    Transplantation; 2002 Jun; 73(11):1808-17. PubMed ID: 12085006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential cardiovascular risk factors in paediatric renal transplant recipients.
    Ferraris JR; Ghezzi L; Waisman G; Krmar RT
    Pediatr Nephrol; 2006 Jan; 21(1):119-25. PubMed ID: 16252106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus.
    Taylor DO; Barr ML; Radovancevic B; Renlund DG; Mentzer RM; Smart FW; Tolman DE; Frazier OH; Young JB; VanVeldhuisen P
    J Heart Lung Transplant; 1999 Apr; 18(4):336-45. PubMed ID: 10226898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation.
    Garlicki M; Czub P; Labuś K; Ehrlich MP; Rdzanek H
    Ann Transplant; 2006; 11(1):24-7. PubMed ID: 17025026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
    Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
    Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-beta system.
    van Riemsdijk IC; Baan CC; Balk AH; Vantrimpont PM; Maat LP; Weimar W
    Transplant Proc; 2002 Aug; 34(5):1864-5. PubMed ID: 12176606
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine A to tacrolimus in pediatric kidney transplant recipients with chronic rejection: changes in the immune responses.
    Ferraris JR; Tambutti ML; Cardoni RL; Prigoshin N
    Transplantation; 2004 Feb; 77(4):532-7. PubMed ID: 15084930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight.
    Neal DA; Gimson AE; Gibbs P; Alexander GJ
    Liver Transpl; 2001 Jun; 7(6):533-9. PubMed ID: 11443583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and structural consequences of early renal allograft injury.
    Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients.
    Rostaing L; Puyoo O; Tkaczuk J; Peres C; Rouzaud A; Cisterne JM; de Preval C; Ohayon E; Durand D; Abbal M
    Clin Transplant; 1999 Oct; 13(5):400-9. PubMed ID: 10515221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience.
    Cantin B; Kwok BW; Shiba N; Valantine HA; Hunt SA; Chan MC
    J Heart Lung Transplant; 2003 Jul; 22(7):723-30. PubMed ID: 12873539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.